| Summary: | Complexes [Ru(η6 C10H14)(Cl2)(HdmoPTA)](OSO2CF3)
(1), [Ru(η6 C10H14)(Cl2)(dmoPTA)] (2) and [Ru(η6 C10H14)(Cl2)-μ-
dmoPTA-1kP:2k2N,N’-MCl2] (M=Zn (3), Co (4), Ni (5), dmoPTA=
3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)
have been synthesized and characterized by elemental
analysis and spectroscopic techniques. The crystal structures
of 1, 3 and 5 were obtained by single-crystal X-ray diffraction.
The antiproliferative activity of the complexes was evaluated
against colon cancer cell line Caco-2/TC7 by using the MTT
protocol. The monometallic ruthenium complexes 1 and 2
were found to be inactive, but the bimetallic complexes 3, 4
and 5 display an increased activity (IC50 3: 9.07�0.27, 4:
5.40�0.19, 5: 7.15�0.30 μM) compared to cisplatin (IC50=
45.6�8.08 μM). Importantly, no reduction in normal cell
viability was observed in the presence of the complexes.
Experiments targeted to obtain information on the possible
action mechanism of the complexes, such as cell cycle, ROS
and gene expression studies, were performed. The results
showed that the complexes display different properties and
action mechanism depending on the nature of metal, M,
bonded to the CH3NdmoPTA atoms.
|
|---|